Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Eloctate

- PMLiVE

Biogen trumpets safety data for Tecfidera follow-up

Much riding on blockbuster's successor

Biomarin

BioMarin eyes haemophilia therapy filing, but data scares investors

Doubts remain on longer term efficacy

- PMLiVE

Am I wrong to be apprehensive about gene therapy?

Is the introduction of gene therapy going to be smooth sailing? Origin's Strategic Solutions Director, Su Smith, shares her thoughts.

Bedrock Healthcare Communications

Biogen Idec building

Biogen’s tofersen shows promise in slowing down ALS

Hope for subset of patients with wasting disease

- PMLiVE

Sobi shows strong growth despite haemophilia competition

Looking to M&A for continued growth

- PMLiVE

Sanofi exits R&D pact with Alnylam on rare disease

Exit also frees up $700m equity investment

- PMLiVE

Biogen’s Spinraza overpriced, says ICER

Cost watchdog warns high price puts pressure on US health system

- PMLiVE

Biogen and Eisai pull plug on Alzheimer’s drug

Further undermines amyloid-targeting approach

Biogen Idec building

Biogen, Eisai cue up BAN2401 readout in Alzheimer’s in 2022

Also considering a trial in preclinical Alzheimer’s subjects

Biogen Idec building

Biogen strikes $800m deal to buy gene therapy firm Nightstar

Will also acquire CHM candidate and a therapy for XLRP

Biogen Idec building

FDA starts review of Biogen’s Tecfidera follow-up for MS

It was initally submitted towards the end of 2018 but had been delayed by US gov shutdown

- PMLiVE

BioMarin prepares for haemophilia A gene therapy data readout, filing

Key long-term data expected in July

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links